Abstract
γ-Secretase proteolyzes a variety of membrane-associated fragments derived from type I integral membrane proteins, including the amyloid β-protein precursor, involved in Alzheimers disease, and the Notch receptor, critical for cellular differentiation. This protease is composed of four integral membrane proteins: presenilin, nicastrin, Aph-1 and Pen-2. Assembly of these four components leads to presenilin autoproteolysis into two subunits, each of which contributes one aspartate to the active site of an aspartyl protease. The protease contains an initial docking site for substrate, where it binds prior to passing between the two presenilin subunits to the internal water-containing active site. The extracellular region of nicastrin also interacts with the N-terminus of the substrate as an essential step in substrate recognition and processing. Modulation of APP processing without interfering with Notch signaling is an important therapeutic goal, and allosteric sites on the protease allow such selective modulation. A better structural and mechanistic understanding of γ-secretase should ultimately allow structure-based design of more potent and selective modulators.
Current Topics in Medicinal Chemistry
Title: γ-Secretase: Structure, Function, and Modulation for Alzheimers Disease
Volume: 8 Issue: 1
Author(s): Michael S. Wolfe
Affiliation:
Abstract: γ-Secretase proteolyzes a variety of membrane-associated fragments derived from type I integral membrane proteins, including the amyloid β-protein precursor, involved in Alzheimers disease, and the Notch receptor, critical for cellular differentiation. This protease is composed of four integral membrane proteins: presenilin, nicastrin, Aph-1 and Pen-2. Assembly of these four components leads to presenilin autoproteolysis into two subunits, each of which contributes one aspartate to the active site of an aspartyl protease. The protease contains an initial docking site for substrate, where it binds prior to passing between the two presenilin subunits to the internal water-containing active site. The extracellular region of nicastrin also interacts with the N-terminus of the substrate as an essential step in substrate recognition and processing. Modulation of APP processing without interfering with Notch signaling is an important therapeutic goal, and allosteric sites on the protease allow such selective modulation. A better structural and mechanistic understanding of γ-secretase should ultimately allow structure-based design of more potent and selective modulators.
Export Options
About this article
Cite this article as:
Wolfe S. Michael, γ-Secretase: Structure, Function, and Modulation for Alzheimers Disease, Current Topics in Medicinal Chemistry 2008; 8 (1) . https://dx.doi.org/10.2174/156802608783334024
DOI https://dx.doi.org/10.2174/156802608783334024 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Emerging Influenza Viruses: Past and Present
Current Molecular Medicine The Face of Uncertainty Eats
Current Drug Abuse Reviews LRP/LR as an Alternative Promising Target in Therapy of Prion Diseases, Alzheimers Disease and Cancer
Infectious Disorders - Drug Targets The Potential of Hydrogen for Improving Mental Disorders
Current Pharmaceutical Design The Anabolic Androgenic Steroid Testosterone Propionate Decreases Recognition Memory in Adult Male Rats
Current Psychopharmacology Safety and Efficacy of Duloxetine in the Treatment of Diabetic Peripheral Neuropathic Pain in Older Patients
Current Drug Safety Endocannabinoids as Regulators of Transient Receptor Potential (TRP)Channels: a Further Opportunity to Develop New Endocannabinoid-Based Therapeutic Drugs
Current Medicinal Chemistry Pediatric Differentiated Thyroid Cancer: When to Perform Conservative and Radical Surgery
Current Pediatric Reviews Recents Patents in the Use of Peroxidases
Recent Patents on Biotechnology Withdrawal Notice: The Relationship between Opium Use and Coronavirus Infection: A Brief Research Report from Iran
Coronaviruses Hunting for Peptide Substrates of Prolyl Oligopeptidase: Classical Versus Non-Classical Bioactive Peptides
CNS & Neurological Disorders - Drug Targets Expression Microarray Proteomics and the Search for Cancer Biomarkers
Current Genomics Exploration of N-arylpiperazine Binding Sites of D2 Dopaminergic Receptor
Mini-Reviews in Medicinal Chemistry Role of Nanomedicines in Delivery of Anti-Acetylcholinesterase Compounds to the Brain in Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Extrasynaptic GABA and Glutamate Receptors in Epilepsy
CNS & Neurological Disorders - Drug Targets The Effects of Cognitive Speed of Processing Training Among Older Adults with Psychometrically- Defined Mild Cognitive Impairment
Current Alzheimer Research Dopaminergic Modulation of Sleep-Wake States
CNS & Neurological Disorders - Drug Targets Radiotracers for Amyloid Imaging in Neurodegenerative Disease: State-of-the-Art and Novel Concepts
Current Medicinal Chemistry The Control of Dopamine Neuron Development, Function and Survival: Insights From Transgenic Mice and The Relevance to Human Disease
Current Medicinal Chemistry Structural Analysis of Relevant Drug Targets for Alzheimer's Disease: Novel Approaches to Drug Development
Current Bioactive Compounds